Rhabdomyosarcomas
Mel-resistant rhabdomyosarcoma cells sensitized to melphalan by TRAIL
Published in Cancer Weekly, April 10th, 2006
"The prognosis for patients with chemo-refractory rhabdomyosarcoma remains poor. The TRAIL is a hopeful candidate for new strategies in chemotherapy," investigators in Germany reported.
"The effects of TRAIL and melphalan (Mel) in the rhabdomyosarcoma cell line TE-671 were investigated by colorimetric caspase assays and flow cytometry," explained K. Kluttermann and colleagues, University of Leipzig. "TRAIL induced the activation of caspases-2, -3 and -8, but not the activation of caspase-9, in the Mel-resistant...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-04-10)
More Articles from Cancer Weekly
- Lung Cancer
Quinuclidinone analogs examined as anti-proliferative agents in lung cancer - Pheochromocytomas
Pheochromocytoma linked to clusterin expression - Prostate Cancer
Prostate cancer linked to 90K/Mac-2 binding protein expression - Acute Myeloid Leukemia
Acute myeloid leukemia outcome not improved after daunorubicin, cytarabine, and thioguanine therapy - Antisense Technology
Antisense oligonucleotide library validates Eg5 as a drug development target - Apoptosis
An adenovirus mutant induces apoptosis and cell-cycle arrest in tumor cells - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
